Innoscripta SE: A value trap to avoid

Why the "Quality Investing" consensus on Innoscripta ($1INN) needs a Bear Case to balance the narrative.

About a month ago, the founders of Innoscripta AG ($1INN) bought back stock. The CEO dropped roughly €3M, and the co-founder added another €100k.

This news has been circulating through the “Quality Investing” ecosystem on Substack. The stock is being pitched by Heavy Moat Investments and René Sellmann.

I have great respect for the work that substack analysts do, but healthy markets require both bull and bear arguments. On Substack, we often see a consensus form, where a stock becomes a “must-own” before the risks are fully vetted. To avoid the dangers of groupthink, it is critical to look at the other side of the trade.

The “Consensus” Trap

We are currently seeing a pattern in the retail value investing community where a narrative forms around a “compounder” with high margins, and suddenly everyone owns it.

• Edenred & Pluxee: Pitched as “moated payment network.” Reality: Regulatory risk crushed them.

• Evolution AB: Pitch as “growth and value in gambling.” Reality: Market saturation and unregulated market risks.

Innoscripta is shaping up to be the next name on this list, and it is arguably the worst. The bull case relies on surface-level metrics, but ignores the structural fragility of the business.

Insider’s “skin in the game” math: €218M Out, €12M In

In the May 2025 IPO of Innoscripta, the founders didn’t raise capital for the company. They used the public markets as a personal ATM.

• Founders’ Cash Out: ~€218 million (plus >€60 million in pre-IPO dividends).

• Company Proceeds: €0.

• Recent “Conviction” Buy: ~€12 million committed (approx. 5.5% of what they took off the table).

When a founder pockets nearly €300 million and puts €12 million back in, that is not “skin in the game.” That is a maintenance fee. It is a calculated cost to prop up the stock price and keep retail investors engaged.

The "Fake SaaS" Revenue Model

The bulls will tell you this is a recurring revenue SaaS business. It is not.

Innoscripta’s revenue depends entirely on the German Forschungszulagengesetz (R&D tax allowance).

• It is NOT automatic: The government doesn’t just send a check every year. Clients must actively spend on R&D, document every hour, and re-apply for costs annually.

• It is Cyclical: If a recession hits and Innoscripta’s clients cut their R&D budgets, Innoscripta’s revenue evaporates. A true SaaS gets paid whether you use the software or not. Innoscripta only gets paid if you spend money.

• Regulatory Risk: They are valued as a €900M company selling a solution to a bureaucratic hurdle. If a future government simplifies the application process (Scenario A) or scraps the subsidy to save money (Scenario B), the company goes to zero.

• Competition Risk: Even if the complexity remains, Innoscripta is trapped in a "no-moat" middle ground: they are blocked from moving up-market by the Big 4 (who will bundle this service for enterprise clients) and are vulnerable in their core SME market to local tax advisors (Steuerberater), who can replicate this form-filling service.

• Transparency & Liquidity Risk: Investors should also be aware of where this stock trades. Innoscripta is listed on the Scale segment of the Frankfurt Stock Exchange, not the Prime Standard.

  • Lower Transparency: This segment has lower reporting requirements than the EU-regulated Prime Standard.

  • Liquidity Risk: Trading volumes in this segment can dry up quickly. If the narrative turns, retail investors might find it very hard to get out.

The Lock-Up Reality

Here is the part the bullish Substacks aren’t highlighting enough. The founders are sitting on a massive pile of remaining shares that are subject to an IPO lock-up until May 2028.

They literally cannot sell the majority of their holdings yet.

If the stock collapses now, their remaining fortune vanishes. Spending a fraction of their IPO winnings to support the share price today is a defensive move to ensure the exit door stays open for 2028.

The Verdict

Don’t be the exit liquidity.